 Furthermore, he believes that Cardinal Health inherits not only Cordis’ large portfolio of interventional cardiology products, but also a wide global footprint and a name in the marketplace.In 2014, Cordis had sales of $780 million with 70% of revenue coming from overseas all of which was attractive to Cardinal Health.2017 Cordis received the CE Mark for its new RAILWAY™ Sheathless Access System, which enables direct access to the radial artery with a guiding catheter and eliminates the need for an introducer sheath, reducing the size of the arterial puncture site up to 2F compared to a conventional sheath system.